Melanox Capsule (Tranexamic Acid)

Adult dose

As tranexamic acid, the usual dosage for adults is 750–2000 mg per day divided into 3–4 oral doses. Adjust according to age and symptoms.

This medication should not be used in patients receiving thrombin. It should not be administered to patients with severe renal failure due to the risk of drug accumulation in the body. Patients allergic to this medication or its components should avoid administration. This medication should not be administered to patients with active thromboembolism. It should be used cautiously in patients with existing thrombus or at risk of thrombosis. Patients with consumptive coagulopathy need careful monitoring when using this medication in combination with other anticoagulants. Patients who are bedridden post-surgery or receiving compression hemostatic treatment are at increased risk of thrombosis and should be cautious when using this medication. Renal failure patients may experience elevated blood drug concentrations, requiring careful administration. This medication contains the dye Yellow No. 5, so patients allergic to this component should use it cautiously. Rarely, shock or hypersensitivity reactions may occur, so if any unusual symptoms arise during administration, it should be stopped immediately and appropriate treatment should be provided. Temporary disturbances in color sensation may occur; if this symptom arises, discontinue the medication. Upper urinary tract bleeding may occur, so be cautious if related symptoms are present. Gastrointestinal symptoms such as loss of appetite, nausea, vomiting, diarrhea, and heartburn may occur. Rarely, adverse reactions such as drowsiness, headache, and thrombosis have been reported. Patients with angioedema require regular eye examinations and liver function tests if used long-term. Patients with irregular menstrual bleeding should avoid using this medication until the cause of bleeding is identified, and if bleeding persists, other treatments should be considered. Using this medication in combination with other thrombus-promoting drugs increases the risk of thrombosis, so they should not be taken together. When used with hormonal contraceptives, the risk of thromboembolism is increased, so non-hormonal contraceptive methods are recommended. Caution should be exercised when administering to pregnant women due to the potential to cross the placenta, and during breastfeeding, the drug may pass into breast milk in small amounts, but is not expected to significantly affect infants. There is insufficient experience using this medication in children under 15 years old, so use it cautiously. Elderly patients may require dosage adjustment due to potentially decreased physical functions. In cases of overdose, symptoms such as nausea, vomiting, and hypotension may appear, requiring immediate consultation with medical personnel and appropriate treatment. Long-term high-dose administration of this medication may result in retinal changes, necessitating caution.

Serious side effects

• Shock
• massive hematuria
• ureteral obstruction
• arterial and venous thrombosis
• thromboembolism

Mild side effects

Itching, rash, flushing, temporary disturbances in color sensation, loss of appetite, nausea, vomiting, diarrhea, heartburn, drowsiness, headache, orthostatic hypotension

This medication should be stored in a tightly sealed container to prevent the ingress of air or moisture. It is advisable to maintain a storage temperature between 1°C and 30°C at room temperature.

Appearance

Hard capsule with an upper orange and lower pale yellow containing white powder

Package unit

30 capsules/bottle, 100 capsules/bottle